Loading…
COSMOS-Mind hints at cognitive benefit; cardiovascular trials are largely null. Weaker case than it looks.
Cardiovascular RCT data is null; cognitive trials show modest signal in older adults.
Our read is Limited Research. The mechanistic story is plausible and the early signals are interesting, but the human outcome data is thin: a limited evidence base (46/100) and only a divided field (48% consensus). At $8/month, taking a daily multivitamin is a bet on preliminary science rather than a settled recommendation.
Pulled the public claims about taking a daily multivitamin from the proponents circulating the claim and weighed them against the more cautious voices (a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
Downside risk on taking a daily multivitamin is low at sensible doses, but low risk is not no risk: individual response varies, and a low-risk intervention is still only worth it if the benefit is real.
A well-designed human outcome trial — the kind that currently does not exist — demonstrating benefit at the doses people actually use.
The effect size is large enough to matter clinically, not just statistically.
Benefits hold across the populations where it's been tested.
The effect size is large enough to matter clinically, not just statistically.
The effect size is large enough to matter clinically, not just statistically.
Benefits hold across the populations where it's been tested.
Most of the support comes from short or small studies.
Most of the support comes from short or small studies.
The headline effect shrinks once you account for trial quality.
Animal-model results don't translate to the human protocol being recommended.
Most of the support comes from short or small studies.